20-F: Zhongchao Inc. Reports Financial Results for Fiscal Year 2024

Zhongchao Inc. announces its financial results for the year ended December 31, 2024, highlighting revenue of $15.9 million and a net loss of $0.3 million.

Summary

• Zhongchao Inc. reported a revenue of $15.9 million for the fiscal year ended December 31, 2024.
• The company experienced a net loss of $0.3 million for the same period.
• The decrease in revenue was primarily caused by a decrease of approximately $6.9 million in revenues from sales of drugs.
• The decrease in revenue was partially offset by the increase in revenue from medical training and education services of approximately $1.3 million.
• The decrease in revenue was also offset by the increase of patient management services of approximately $1.9 million.
• The company's gross profit margin was 56.2% for the fiscal year 2024.
• Selling and marketing expenses decreased by approximately $2.7 million, or 40.2%, from approximately $6.7 million for the fiscal year ended December 31, 2023 to approximately $4.0 million for the fiscal year ended December 31, 2024.
• General and administrative expenses decreased by approximately $1.7 million, or 25.5%, from approximately $6.7 million for the fiscal year ended December 31, 2023 to approximately $5.0 million for the fiscal year ended December 31, 2024.
• Research and development expenses decreased by approximately $0.2 million, or 50.9%, from approximately $0.5 million for the fiscal year ended December 31, 2023 to approximately $0.3 million for the fiscal year ended December 31, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with decreased revenue and a net loss, but also reduced operating expenses. The sentiment is neutral, reflecting both positive and negative aspects.

Positives

• The company's gross profit margin was 56.2% for the fiscal year 2024.
• Selling and marketing expenses decreased by approximately $2.7 million, or 40.2%, from approximately $6.7 million for the fiscal year ended December 31, 2023 to approximately $4.0 million for the fiscal year ended December 31, 2024.
• General and administrative expenses decreased by approximately $1.7 million, or 25.5%, from approximately $6.7 million for the fiscal year ended December 31, 2023 to approximately $5.0 million for the fiscal year ended December 31, 2024.
• Research and development expenses decreased by approximately $0.2 million, or 50.9%, from approximately $0.5 million for the fiscal year ended December 31, 2023 to approximately $0.3 million for the fiscal year ended December 31, 2024.

Negatives

• The company experienced a net loss of $0.3 million for the fiscal year ended December 31, 2024.
• The decrease in revenue was primarily caused by a decrease of approximately $6.9 million in revenues from sales of drugs.

Risks

• The company's operations are carried out in China, and its business, financial condition, and results of operations may be influenced by the political, economic, and legal environments in the PRC.
• The company's ability to pay dividends depends upon dividends paid by its PRC subsidiary, which is subject to restrictions on its ability to make distributions.
• The company identified material weaknesses in its internal control over financial reporting, which could affect its ability to accurately report financial results or prevent fraud.

Future Outlook

The company intends to continue to use these funds to grow our business primarily by: Strengthen our brand awareness of MDMOOC and Zhongxin Health Expand and enhancement of medical course content Grow medical professional user community Recruit more experienced editorial staff, and Develop new teaching platforms Explore the business in services for cancer patients support

Industry Context

The announcement reflects the financial performance of a company operating in the healthcare information and education sector in China, a market with increasing demand for online medical training and patient management services.

Comparison to Industry Standards

• It is difficult to compare Zhongchao Inc. directly to global benchmarks due to its unique business model and focus on the Chinese market.
• However, the company's performance can be assessed against other players in the Chinese online healthcare and education space.
• Companies like Dingdang Health and Ali Health are major players in the online healthcare market in China, but their business models differ significantly from Zhongchao Inc.'s focus on medical training and education.
• The company's revenue and profitability should be compared to those of other companies providing similar services in China, but such data may not be readily available.

Stakeholder Impact

• Shareholders: The net loss may negatively impact shareholder value.
• Employees: Cost-cutting measures may affect employee compensation and job security.
• Customers: The company's ability to invest in new services and products may be affected.

Key Dates

Keywords

financial results, revenue, net loss, gross profit, operating expenses, China, healthcare, medical training, pharmaceutical, Zhongchao Inc.